Ben Hutchins

Ben Joined Mythic Therapeutics in November 2020 to build out technical operations and lead all CMC-related activities in support of bringing the company’s lead ADC program to the clinic. His work at Mythic is informed by his extensive experience in the process development, scale-up, technology transfer, and manufacturing support of biologics, small molecules, and antibody-drug conjugates (ADCs).

Prior to Mythic, Ben was Director of CMC at Editas Medicine, where he led the CMC team in the development of EDIT-301, an autologous cell-therapy medicine to treat sickle cell disease. Before that, Ben spent a decade at ImmunoGen, where he served as the director of CMC strategy, overseeing the development of numerous ADCs, and also led the team responsible for designing the conjugation processes used to manufacture the ADCs.

Ben received his Ph.D. in chemistry from Penn State and completed a postdoctoral fellowship at The Scripps Research Institute developing novel Fab conjugates through unnatural amino acid incorporation and conjugation.